Genomics Report
: Analysis on the Market, Trends, and TechnologiesThe genomics sector is scaling into a high-value analytics industry as sequencing capacity commoditizes and interpretation captures margin; the internal genomics trend report projects a 15.0% market CAGR with a forecasted market size of USD 186,640,000,000 by 2035, framing strategic bets on data platforms and clinical integration as the primary value drivers.
We updated this report 6 days ago. Missing information? Contact us to add your insights.
Topic Dominance Index of Genomics
The Topic Dominance Index combines the distribution of news articles that mention Genomics, the timeline of newly founded companies working within this sector, and the share of voice within the global search data
Key Activities and Applications
- Large-scale whole-genome sequencing for population studies and clinical diagnostics, used to populate reference panels and improve variant calling for clinical use
- Functional genomics experiments (CRISPR screens, perturb-seq, pooled screens) to map gene function and nominate therapeutic targets for drug development.
- Clinical genomics interpretation and variant curation to produce actionable reports for oncology, rare disease, and pharmacogenomics decisions Genomenon.
- Consumer and personal genomics services that combine sequencing or genotyping with subscription reporting and longitudinal data collection Precedenceresearch - Consumer Genomics Market Size to Hit USD 18.83 Bn By 2034.
- Metagenomic sequencing for infectious-disease diagnostics, microbiome therapeutics, and environmental monitoring, enabling unbiased pathogen detection and antimicrobial resistance profiling.
Emergent Trends and Core Insights
- AI-first interpretation stacks: companies deploy ML models to compress variant annotation time and prioritize clinically relevant findings, converting raw sequence into revenueable clinical decisions
- Multi-omics integration: combining genomics with transcriptomics and proteomics increases predictive power for phenotype assignment and drug response, shifting productization from single-assay reports to integrated clinical intelligence A New Proteomics Assay Bridges the Gap between Genotype and Phenotype.
- Population-aware reference models and graph genomes: methods that use diverse, population-level data and graph references reduce mapping bias and improve calling in highly polymorphic regions, raising clinical sensitivity for non-European ancestries.
- Single-cell and spatial genomics moving into translational pipelines: these methods reveal cellular heterogeneity relevant to oncology and immunotherapy response and attract platform and services investment
- Data sovereignty and consumer-centric data marketplaces: architectures that let individuals control and monetize genomic data surface as competitive alternatives to centralized biobanks, altering partnership dynamics for research access thebusinessresearchcompany - Genomics Market 2025.
Technologies and Methodologies
- Next-Generation Sequencing (NGS) optimized for throughput and cost per base remains core to sample acquisition and populating variant catalogs market.us - Genomics Market.
- Long-read and optical mapping platforms (HiFi long reads, nanopore, optical genome mapping) resolve structural variants and paralogous regions that short reads cannot, improving diagnostics for complex genomic loci HiFi Sequencing to Distinguish Highly Similar Paralogous Genes Bionano Genomics, Inc..
- Graph-reference and compressed genotype fingerprinting accelerate population-scale comparisons while reducing storage and supporting privacy-preserving matches.
- Automated phenotype prioritization and HPO-driven variant interpretation pipelines shorten diagnostic turnaround and standardize clinical reports for labs and hospitals Nostos Genomics GmbH.
- Cloud-native, standards-aware genomic platforms (e.g. ISO/IEC 23092 MPEG-G support) that reduce storage footprint and enable interoperable applications across providers
Genomics Funding
A total of 3.3K Genomics companies have received funding.
Overall, Genomics companies have raised $369.4B.
Companies within the Genomics domain have secured capital from 13.8K funding rounds.
The chart shows the funding trendline of Genomics companies over the last 5 years
Genomics Companies
GenomSys
GenomSys builds an ISO/IEC 23092 (MPEG-G) based genomic platform to compress storage needs and accelerate time to market for genomic apps. The company focuses on interoperability and regulatory readiness for medical device software, positioning itself for hospital and clinical lab integrations where data standards matter. Its platform claims material cost and time savings for scaling genomic services
SIVOTEC BioInformatics
SIVOTEC offers the GENA™ AI platform to accelerate SNP array and Mendelian disease interpretation, reporting dramatic time savings for clinical labs and reducing analyst hours per case. The company targets commercial labs and hospitals with a workflow automation value proposition that directly addresses the sector's shortage of skilled genomics interpreters
Genepath Laboratories
Genepath specializes in accredited newborn and pediatric screening panels that detect treatable conditions early. By focusing on validated, high-volume neonatal programs and government pilots, the company competes on clinical trust and regulatory compliance rather than price, targeting a predictable and high-impact clinical market segment
Genteract
Genteract uses statistical and machine learning methods to discover gene-environment interactions with high statistical power and applies those insights to pharmacogenomics and clinical trial optimization. The firm positions its models as tools to reduce ineffective prescribing and to rescue or relaunch drugs with companion diagnostics
Genomes.io
Genomes.io builds a privacy-first DNA vault and marketplace combining encryption and blockchain concepts to let individuals control and monetize their genomic data. The platform targets individuals and researchers, proposing repeat consent models that change how research cohorts source data and how participants share benefits
Gain a competitive edge with access to 13.4K Genomics companies.
13.4K Genomics Companies
Discover Genomics Companies, their Funding, Manpower, Revenues, Stages, and much more
Genomics Investors
Leverage TrendFeedr’s sophisticated investment intelligence into 11.3K Genomics investors. It covers funding rounds, investor activity, and key financial metrics in Genomics. investors tool is ideal for business strategists and investment experts as it offers crucial insights needed to seize investment opportunities.
11.3K Genomics Investors
Discover Genomics Investors, Funding Rounds, Invested Amounts, and Funding Growth
Genomics News
TrendFeedr’s News feature provides a historical overview and current momentum of Genomics by analyzing 65.0K news articles. This tool allows market analysts and strategists to align with latest market developments.
65.0K Genomics News Articles
Discover Latest Genomics Articles, News Magnitude, Publication Propagation, Yearly Growth, and Strongest Publications
Executive Summary
The strategic battleground in genomics has shifted from sequencing throughput to data utility. Firms that win will convert raw sequence into clinically credible, standards-compliant intelligence at scale, while managing privacy and population representativeness. Near term, invest in analytic platforms that: (1) reduce interpretation time and cost through validated AI and phenotype-driven pipelines; (2) adopt standards that lower integration friction with clinical systems and regulators; and (3) secure differentiated data assets that improve performance for underrepresented populations or rare diseases. Market growth projections and internal forecasts justify allocating capital to companies that move up the value chain from data generation to actionable clinical decision support.
Interested in contributing your expertise on trends and tech? We’d love to hear from you.
